| Patient-derived xenograft models: an emerging platform for translational cancer research M Hidalgo, F Amant, AV Biankin, E Budinská, AT Byrne, C Caldas, ... Cancer discovery 4 (9), 998-1013, 2014 | 1975 | 2014 |
| MET signalling: principles and functions in development, organ regeneration and cancer L Trusolino, A Bertotti, PM Comoglio Nature reviews Molecular cell biology 11 (12), 834-848, 2010 | 1459 | 2010 |
| Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens FM Behan, F Iorio, G Picco, E Gonçalves, CM Beaver, G Migliardi, ... Nature 568 (7753), 511-516, 2019 | 1388 | 2019 |
| Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of … A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ... The Lancet Oncology 17 (6), 738-746, 2016 | 1164 | 2016 |
| A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer A Bertotti, G Migliardi, F Galimi, F Sassi, D Torti, C Isella, D Corà, ... Cancer discovery 1 (6), 508-523, 2011 | 1107 | 2011 |
| Drug development of MET inhibitors: targeting oncogene addiction and expedience PM Comoglio, S Giordano, L Trusolino Nature reviews Drug discovery 7 (6), 504-516, 2008 | 1023 | 2008 |
| Scatter-factor and semaphorin receptors: cell signalling for invasive growth L Trusolino, PM Comoglio Nature reviews cancer 2 (4), 289-300, 2002 | 926 | 2002 |
| Interrogating open issues in cancer precision medicine with patient-derived xenografts AT Byrne, DG Alférez, F Amant, D Annibali, J Arribas, AV Biankin, A Bruna, ... Nature Reviews Cancer 17 (4), 254-268, 2017 | 779 | 2017 |
| Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ... Cancer discovery 3 (6), 658-673, 2013 | 775 | 2013 |
| Stromal contribution to the colorectal cancer transcriptome C Isella, A Terrasi, SE Bellomo, C Petti, G Galatola, A Muratore, A Mellano, ... Nature genetics 47 (4), 312-319, 2015 | 713 | 2015 |
| A signaling adapter function for α6β4 integrin in the control of HGF-dependent invasive growth L Trusolino, A Bertotti, PM Comoglio Cell 107 (5), 643-654, 2001 | 574 | 2001 |
| The genomic landscape of response to EGFR blockade in colorectal cancer A Bertotti, E Papp, S Jones, V Adleff, V Anagnostou, B Lupo, M Sausen, ... Nature 526 (7572), 263-267, 2015 | 528 | 2015 |
| EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer V Amodio, R Yaeger, P Arcella, C Cancelliere, S Lamba, A Lorenzato, ... Cancer discovery 10 (8), 1129-1139, 2020 | 463 | 2020 |
| Adaptive mutability of colorectal cancers in response to targeted therapies M Russo, G Crisafulli, A Sogari, NM Reilly, S Arena, S Lamba, A Bartolini, ... Science 366 (6472), 1473-1480, 2019 | 459 | 2019 |
| Effective drug combinations in breast, colon and pancreatic cancer cells P Jaaks, EA Coker, DJ Vis, O Edwards, EF Carpenter, SM Leto, L Dwane, ... Nature 603 (7899), 166-173, 2022 | 439 | 2022 |
| The Met tyrosine kinase receptor in development and cancer A Gentile, L Trusolino, PM Comoglio Cancer and metastasis reviews 27 (1), 85-94, 2008 | 409 | 2008 |
| Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy PM Comoglio, L Trusolino, C Boccaccio Nature Reviews Cancer 18 (6), 341-358, 2018 | 375 | 2018 |
| Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3 C Sun, S Hobor, A Bertotti, D Zecchin, S Huang, F Galimi, F Cottino, ... Cell reports 7 (1), 86-93, 2014 | 373 | 2014 |
| HER2 activating mutations are targets for colorectal cancer treatment SM Kavuri, N Jain, F Galimi, F Cottino, SM Leto, G Migliardi, ... Cancer discovery 5 (8), 832-841, 2015 | 330 | 2015 |
| Interactions between growth factor receptors and adhesion molecules: breaking the rules PM Comoglio, C Boccaccio, L Trusolino Current opinion in cell biology 15 (5), 565-571, 2003 | 330 | 2003 |
Andrea BertottiUniversity of Torino - School of MedicineVerified email at ircc.it
